Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 50/12.5/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 75/18.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 100/25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 125/31.25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 150/37.5/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 175/43.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 200/50/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; powdered cellulose; trehalose dihydrate; hyprolose; carmellose sodium; sodium sulfate; magnesium stearate; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; trehalose dihydrate; hyprolose; sodium sulfate; powdered cellulose; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.